Immune Related Adverse Events of Checkpoint Inhibitors
ACR on Air
00:00
Managing Immune-Related Adverse Events of Checkpoint Inhibitors
The chapter delves into the complexities of treating immune-related adverse events (IRA-Es) caused by combination therapies like CTLA4 and PD-1 or PDL1 inhibitors, emphasizing the need for a multidisciplinary approach involving oncologists and rheumatologists. It discusses the model adopted at Hopkins for handling IRAEs, highlighting a dedicated team of specialists collaborating with oncologists. The setup in the clinic to manage these adverse events is detailed, focusing on specialized equipment and refining systems for improved patient care.
Transcript
Play full episode
